Navigation Links
Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
Date:3/28/2011

Cellular and Molecular Biology 27Poster Section:

2Poster Board:

5The above abstracts are currently available online for viewing through the AACR 2011 Meeting website at: http://www.aacr.org/home/scientists/meetings--workshops/aacr-102nd-annual-meeting-2011/abstracts.aspx

KRX-0401 (perifosine) is in-licensed by Keryx from AEterna Zentaris Inc. in the United States, Canada and Mexico.

ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA.
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
3. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
4. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
5. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
6. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
7. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
8. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
9. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
10. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
11. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... VIEW, Calif. , July 30, 2015 ... it will release its second quarter 2015 financial results ... 2015.   In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
(Date:7/30/2015)... , July 30, 2015  Unichem Pharmaceuticals ( ... lot of Hydrochlorothiazide tablets 25 mg 1000-count bottle to ... a precautionary measure due to the identification of a ... The risk associated with mistakenly taking ... the increased probability of experiencing Clopidogrel,s side effects which ...
(Date:7/30/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ) ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... notice it received on May 21, 2015 from the ... was below certain of the Exchange,s continued listing standards, ... the NYSE MKT Company Guide, due to the delay ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... KNSY ), today announced that it has entered into ... under which DSM has agreed to acquire all of the common ... a merger with a subsidiary of DSM, for $38.50 per share ... entered into the merger agreement with DSM, as the transaction will ...
... Synteract , Inc., a full-service contract research organization ... therapies to combat the growing issue of antibiotic resistance, ... fundraising walk to benefit the Cystic Fibrosis (CF) ... behalf of Aptalis Pharma) are also working together on ...
Cached Medicine Technology:Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 2Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 3Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 4Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 5Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 6Synteract and Rempex Partner in "Great Strides" Walk to Support Cystic Fibrosis Cure 2
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, Twitter, Linkedin and ... their social media profiles to better connect with the public. The agency website ... information, share insights and opinions. The Rally Insurance Group, Inc.’s pledge to provide ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... According to ... cosmetic experts gathered to see if they could reach a consensus on the steps ... augmentation and facelifts. Overall, the group reached 90 percent consensus on a series of ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2015 New York ... family members, medical professionals, and researchers, covering a variety of topics related to ... collaborative effort between the Mesothelioma Applied Research Foundation and Memorial Sloan Kettering Cancer ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... been recognized in the 2015 Aster Awards national competition for a marketing communications ... Ocean City and surrounding communities in Coastal Maryland and Southern Delaware. , A ...
(Date:7/31/2015)... ... 31, 2015 , ... Recently, ZKB filed another federal lawsuit ... (Case No. 3:15-cv-00397) involving the Implanon® contraceptive implant . , As described ... Implanon® implants, inability to locate the implants, unsuccessful and invasive attempts at implant ...
Breaking Medicine News(10 mins):Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3
... MAQUET Cardiovascular LLC,announced today that it was served ... (Terumo CSC) in the United States District,Court for ... that,MAQUET,s VASOVIEW Endoscopic Vessel Harvesting Systems infringe a ... patent infringement complaints against,Terumo CSC and Terumo Corporation ...
... SANTA YNEZ VALLEY, Calif., Sept. 2 Platinum Performance,client McLain ... Summer Olympics in Beijing, China, on August 19, as "probably ... sport.", Winning the first ever jump-off in Olympic Games ... the Team Show Jumping title at the Hong Kong,Olympic Equestrian ...
... CORAL GABLES, Fla., Sept. 2 MBF ... publicly traded special purpose,acquisition company, announced today ... MBH,s proposed acquisition of Critical Homecare Solutions,Holdings, ... stock purchase,agreement dated February 6, 2008 (the ...
... LANCASTER, Pa., Sept. 2 Herley Industries,Inc. (Nasdaq: ... manufacture of,microwave technology solutions for the defense, aerospace and ... a division of Jefferies & Company, Inc., as its ... strategic alternatives., Myron Levy, Chairman and CEO, said, ...
... and Providers Contain Costs and ... Improve Patient Outcomes Together, HOUSTON, Sept. ... Oncology, a service division that offers a first-time,opportunity for oncologists ... for the complexity of cancer,care. With a unique focus on ...
... even a year after routine was stopped, study says ... may help treat memory problems in adults, according to ... 138 people age 50 and older at increased risk ... led to modest improvements in cognitive function in adults ...
Cached Medicine News:Health News:MAQUET Cardiovascular Responds to Terumo Complaint About VASOVIEW Endoscopic Vessel Harvesting Systems 2Health News:Platinum Performance Clients Take Home Medals for the USA 2Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 2Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 3Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 4Health News:Herley Industries, Inc. Engages Jefferies Quarterdeck to Explore Strategic Alternatives 2Health News:US Oncology Launches New Services Division: Innovent Oncology 2Health News:US Oncology Launches New Services Division: Innovent Oncology 3Health News:US Oncology Launches New Services Division: Innovent Oncology 4Health News:Exercise May Help Prevent Age-Related Memory Loss 2
Straight shafts with 16 mm long platform. Lengthwise serrated jaws with cross serrated tips. Serrated handle with polished finish. Platform: 2.4 mm wide....
Straight shafts with fitted v-grooved 15 mm platform. Serrated handle with polished finish....
Smooth tip forceps allow the surgeon to manipulate and smooth the corneal flap in Lasik procedures. Tip angled 10 mm from tip. Manufactured in titanium....
Straight shafts with 1 x 2 teeth. Flat handle with haoles and polished finish. Delicate teeth. Most popular size or model....
Medicine Products: